Browse the evidence

Inkretin-basierte Medikamente (GLP-1- und GIP/GLP-1-Rezeptoragonisten) und SGLT-2-Inhibitoren (SGLT2i) ermöglichen eine bislang nicht erreichte Gewichtsreduktion und reduzieren nachweislich kardiovaskuläre Ereignisse (MACE).

Practitioners should consider these medications as effective options for weight management and cardiovascular risk reduction.

Die Kombination von GLP-1-Rezeptoragonisten und SGLT2i zeigt additive Vorteile und wird leitliniengerecht bei Typ-2-Diabetes mit hohem Risiko empfohlen.

Healthcare providers should consider this combination therapy for high-risk type 2 diabetes patients.

Advanced pharmacotherapy with GLP-1 receptor agonists can achieve 15%–20% weight loss.

Clinicians can consider GLP-1 receptor agonists as an effective pharmacotherapy option for weight loss.

Recent antiobesity drugs have shown weight loss effects of 12%–17% and can resolve NASH in some patients.

Consider the use of antiobesity medications as part of a comprehensive treatment plan for NASH.

Tirzepatide has demonstrated superior efficacy in promoting weight loss and maintaining a healthy body weight compared to traditional incretin therapies.

Tirzepatide may be a more effective option for weight management in patients with obesity.

Dual agonists improve glycemic control and promote substantial weight loss.

Practitioners can consider dual agonists as effective options for improving glycemic control and aiding weight loss in patients with metabolic diseases.

Phase 3 clinical trials showed superior efficacy of tirzepatide compared to existing pharmacotherapies, reaching body weight reductions of approximately 22.5% and hemoglobin A1c (HbA1c) reductions of up to 2.4 percentage points.

Tirzepatide may be a more effective treatment option for weight loss and glycemic control in patients with obesity and T2DM.

Phase 2 trials of retatrutide revealed weight reductions approaching 24.2% over 48 weeks.

Retatrutide may offer substantial weight loss benefits for individuals with obesity over a 48-week period.

Antiobesity drugs can lead to a mean total body weight loss of 10% to nearly 20% at high dosages.

Antiobesity medications can be effective for weight loss in specific patient populations.

Tirzepatide significantly improved physical function compared with placebo, with a mean difference of 10.10 points in the IWQOL-Lite-CT physical function subscale.

Practitioners can consider tirzepatide as an effective treatment to enhance physical function in adults with overweight or obesity.

Once-monthly maridebart has produced clinically meaningful weight loss of approximately 12–16% in adults without diabetes and 8–12% in those with type 2 diabetes.

Practitioners can expect significant weight loss outcomes with once-monthly maridebart in their patients.

GLP-1 receptor agonists (GLP-1 RAs) are used to treat type 2 diabetes and obesity due to benefits in glycemic control, weight loss, and cardiovascular risk reduction.

Practitioners should consider GLP-1 RAs for managing type 2 diabetes and obesity.

Both tirzepatide and semaglutide significantly improved weight, body mass index, hemoglobin A1c, fasting plasma glucose, and triglyceride levels in solid-organ transplant recipients.

Both medications can be considered effective options for managing diabetes in transplant patients.

Participants without type 2 diabetes (T2D) achieved significantly greater weight loss than those with T2D, with a median weight loss of 11.21% vs 5.48%, P < 0.001.

Practitioners should consider diabetes status when setting weight loss expectations for patients.

Tirzepatide was associated with greater weight loss compared with semaglutide, with a median weight loss of 8.60% vs 5.62%, P = 0.023.

Clinicians may prefer tirzepatide over semaglutide for better weight loss outcomes.

Younger age, tirzepatide use, and GLP1 treatment naivety were identified as determinants of faster achievement of ≥10% weight loss.

Understanding these determinants can help tailor weight loss strategies for individuals.

Adding testosterone undecanoate to tirzepatide in late responders resulted in significantly greater body weight and fat mass reduction compared to tirzepatide monotherapy (P<0.05).

Clinicians may consider adding testosterone therapy to enhance weight loss outcomes in specific patient populations.

Testosterone undecanoate addition led to significant lean body mass recovery compared to tirzepatide monotherapy (66.1±3.1 kg vs. 63.4±3.0 kg, P<0.01).

Adding testosterone therapy may help preserve or enhance muscle mass in patients struggling with weight loss.

GLP-1 receptor agonists achieve clinically significant weight loss of 15–22.5% total body weight.

GLP-1 RAs can be considered effective options for achieving significant weight loss in obesity management.

GLP-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonists provide clinically meaningful weight loss of approximately 15%–21% at 68–72 weeks in major trials.

Practitioners can expect significant weight loss in patients using GLP-1 therapies over the specified duration.

Semaglutide reduces the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 20% in adults with established cardiovascular disease.

GLP-1 therapies may also provide cardiovascular benefits, which is important for patient management.

Incretin-based therapies have transformed the management of obesity and type 2 diabetes, with GLP-1RAs achieving levels of weight loss that begin to narrow the gap with metabolic surgery in selected populations.

Practitioners should consider incretin-based therapies as effective options for weight management in patients with obesity and type 2 diabetes.

Participants using the program plus medication were more likely to achieve clinically significant weight loss, with odds ratios ranging from 1.46 to 2.57 for ≥5% weight loss across timepoints.

Integrating a behavioral support app with GLP-1 RA treatment can significantly enhance weight loss outcomes.

Medication type was the strongest determinant of weight loss over time, with tirzepatide producing greater early reductions.

Choosing the right GLP-1 RA can significantly impact weight loss success.